newsfilter
← Latest News
GlobeNewswire·

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway guidance